ATXS - מחירי תחזית של אנליסטים Astria Corp

Astria Therapeutics (ATXS) focuses on developing treatments for hereditary angioedema, assuming high early-stage development risks. The company relies on laboratory partnerships and patent acquisitions for molecule delivery, which this chart confirms with a market asset value of 12.97. The business model is based on high margins from global sales following the registration of unique formulas.

Astria Therapeutics (ATXS) is developing a scalable model in the field of immunology, where patent potential and an asset-light structure drive future margins. The average analyst price target of 12.97 represents a weighted average fair value assessment from institutional experts, allowing investors to determine the actual margin of safety and filter out market noise when evaluating the fundamental value of this pre-revenue biotech.